Arkolith/Insider Trading/SGMT/Form 4

Kemble George

Executive Chairman, DirectorSagimet Biosciences Inc. (SGMT) · full profile →Form 4 · filed Jul 25, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$75K
Net Open-Market Flow
-$75K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 23, 2024Sell(S)24K$3.17$75K119K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-24-082630) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML